These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 8122821)

  • 1. Interview with Ivan M. Roitt. What is going to happen tomorrow as far as glycosylation of IgG is concerned?. Interview by P. Youinou.
    Roitt IM
    Ann Med Interne (Paris); 1993; 144(6):389-91. PubMed ID: 8122821
    [No Abstract]   [Full Text] [Related]  

  • 2. Interview with Joachim Robert Kalden. What is going to happen tomorrow as far as DNA and anti-DNA antibodies are concerned?. Interview by P. Youinou.
    Kalden JR
    Ann Med Interne (Paris); 1993; 144(7):463-4. PubMed ID: 8141512
    [No Abstract]   [Full Text] [Related]  

  • 3. Interview with Joaquim Coll. What is going to happen tomorrow as far as secondary Sjögren's syndrome is concerned?. Interview by P. Youinou.
    Coll J
    Ann Med Interne (Paris); 1993; 144(4):257-9. PubMed ID: 8368718
    [No Abstract]   [Full Text] [Related]  

  • 4. Interview with Frank Hay. What is going to happen tomorrow as far as rheumatoid factor is concerned?
    Hay F
    Ann Med Interne (Paris); 1995; 146(7):479-80. PubMed ID: 8787288
    [No Abstract]   [Full Text] [Related]  

  • 5. Interview with Robert Schwartz. What is going to happen tomorrow in the field exploring the relationship between viruses and autoimmunity?. Interview by P. Youinou.
    Schwartz R
    Ann Med Interne (Paris); 1992; 143(6):419-20. PubMed ID: 1295397
    [No Abstract]   [Full Text] [Related]  

  • 6. [An interview with Jean-Michel Dayer: what is going to happen tomorrow in the field of cytokines?. Interview by P Youinou].
    Dayer JM
    Ann Med Interne (Paris); 1992; 143(7):445-7. PubMed ID: 1300865
    [No Abstract]   [Full Text] [Related]  

  • 7. [Interview with Dominique Charron. What is going to happen tomorrow in the understanding of the functioning of HLA molecules?. Interview by P. Youinou].
    Charron D
    Ann Med Interne (Paris); 1995; 146(1):25-8. PubMed ID: 7741390
    [No Abstract]   [Full Text] [Related]  

  • 8. Interview with Graham Hughes. What is going to happen tomorrow in the field of anti-phospholipid antibodies?. Interview by P. Youinou.
    Hughes G
    Ann Med Interne (Paris); 1992; 143(6):417-8. PubMed ID: 1295396
    [No Abstract]   [Full Text] [Related]  

  • 9. [An interview with Sylviane Muller by P Youinou. What is going to happen tomorrow in the field of synthetic peptides of autoantigens?].
    Muller S
    Ann Med Interne (Paris); 1993; 144(5):319-22. PubMed ID: 8291840
    [No Abstract]   [Full Text] [Related]  

  • 10. [Interview with Pierre Godeau, President of the Société Nationale Française de Médecine Interne. What is going to happen tomorrow in internal medicine?. Interview by Pierre Youinou].
    Godeau P
    Ann Med Interne (Paris); 1994; 145(1):3-6. PubMed ID: 8192278
    [No Abstract]   [Full Text] [Related]  

  • 11. Interview with Norman Talal. What is going to happen tomorrow as far as Sjögren's syndrome is concerned?
    Talal N
    Ann Med Interne (Paris); 1993; 144(1):21-2. PubMed ID: 8503601
    [No Abstract]   [Full Text] [Related]  

  • 12. Interview with Peter Lydyard. What is going to happen tomorrow as far as heat-shock proteins are concerned?
    Lydyard P
    Ann Med Interne (Paris); 1993; 144(2):97-8. PubMed ID: 8333667
    [No Abstract]   [Full Text] [Related]  

  • 13. Interview with Jean-Pierre Revillard. What is going to happen tomorrow as far as treatment of autoimmune disorders is concerned?
    Revillard JP
    Ann Med Interne (Paris); 1997; 148(1):11-4. PubMed ID: 9137693
    [No Abstract]   [Full Text] [Related]  

  • 14. Does a glycosylation defect of IgG reduce their binding to the corresponding receptors?
    Adler Y; Casburn-Budd R; Lamour A; Shoenfeld Y; Youinou P
    Ann Med Interne (Paris); 1994; 145(1):32-5. PubMed ID: 8192279
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunoglobulin G glycosylation and clinical outcome in rheumatoid arthritis during pregnancy.
    Alavi A; Arden N; Spector TD; Axford JS
    J Rheumatol; 2000 Jun; 27(6):1379-85. PubMed ID: 10852257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IgG glycosylation status as a clinical predictor of rheumatoid arthritis: comment on the article by Kim and Weisman.
    Isenberg DA; Young A
    Arthritis Rheum; 2000 Nov; 43(11):2617-8. PubMed ID: 11083296
    [No Abstract]   [Full Text] [Related]  

  • 17. Modified immunoglobulin G glycosylation pattern during turpentine-induced acute inflammation in rats.
    Canellada A; Margni RA
    Medicina (B Aires); 2002; 62(3):249-55. PubMed ID: 12150009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant glycosylation of Igg heavy chain in multiple myeloma.
    Aurer I; Lauc G; Dumić J; Rendić D; Matisić D; Milos M; Heffer-Lauc M; Flogel M; Labar B
    Coll Antropol; 2007 Mar; 31(1):247-51. PubMed ID: 17598409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Two year investigation of glycosylation profiles in serum IgG from a patient with multiple myeloma].
    Oita T; Yagi H; Yamashiro A; Sakizono K; Nagai K; Kasakura S; Kato K; Takahashi N
    Rinsho Byori; 2007 Jul; 55(7):626-9. PubMed ID: 17718058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Site-specific N-glycosylation of chicken serum IgG.
    Suzuki N; Lee YC
    Glycobiology; 2004 Mar; 14(3):275-92. PubMed ID: 14693911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.